Adjuvant dendritic cell-based tumour vaccination for children with malignant brain tumours

Pediatric Blood and Cancer

Volumn 54, Issue 4, 2010, Pages 519-525

  Ardon, Hilko ^a   De Vleeschouwer, Steven ^a   Van Calenbergh, Frank ^a   Claes, Laurence ^b   Kramm, Christof M ^c   Rutkowski, Stefan ^d   Wolff, Johannes E A ^e   Van Gool, Stefaan W ^a  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^b UNIVERSITY OF LEUVEN   (Belgium)

^c MARTIN LUTHER UNIVERSITÄT HALLE WITTENBERG   (Germany)

^d UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^e UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Brain tumours; Dendritic cell vaccination; Immunotherapy

Indexed keywords

CORTICOSTEROID; DENDRITIC CELL VACCINE; IMIQUIMOD; TUMOR ANTIGEN; TUMOR VACCINE;

ADJUVANT THERAPY; ADOLESCENT; ADULT; ARTICLE; ASTROCYTOMA; BLOOD SAMPLING; BRAIN TUMOR; CANCER CHEMOTHERAPY; CANCER IMMUNIZATION; CANCER MORTALITY; CANCER RELAPSE; CANCER SURGERY; CANCER SURVIVAL; CANCER SURVIVOR; CELL LINE; CELL LYSATE; CHILD; CLINICAL ARTICLE; DENDRITIC CELL; EPENDYMOMA; EXPLORATORY RESEARCH; FATIGUE; FEMALE; FEVER; FLU LIKE SYNDROME; FOLLOW UP; GLIOBLASTOMA; GLIOMA; HEADACHE; HUMAN; HUMAN TISSUE; INFANT; LEUKAPHERESIS; MALE; MALIGNANT NEOPLASTIC DISEASE; MEDULLOBLASTOMA; MONOCYTE; NEUROECTODERM TUMOR; NEWBORN; OVERALL SURVIVAL; PERIPHERAL BLOOD MONONUCLEAR CELL; PRESCHOOL CHILD; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PRURITUS; QUALITY OF LIFE; RECURRENT DISEASE; RHABDOID TUMOR; SCHOOL CHILD; TERATOMA; TUMOR CELL; VACCINATION REACTION; VOMITING;

ANTINEOPLASTIC AGENTS; BRAIN NEOPLASMS; CANCER VACCINES; CHILD; COMBINED MODALITY THERAPY; DENDRITIC CELLS; FEMALE; HUMANS; MALE; QUALITY OF LIFE; VACCINATION;

EID: 77649123099     PISSN: 15455009     EISSN: 15455017     Source Type: Journal    
DOI: 10.1002/pbc.22319     Document Type: Article

References (41)

1. Kleihues P, Soylemezoglu F, Schauble B, et al. Histopathology, classification, and grading of gliomas. Glia 1995;15:211-221.
2. Bao S, Wu Q, McLendon RE, et al. Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature 2006;444:756-760.
3. Eramo A, Ricci-Vitiani L, Zeuner A, et al. Chemotherapy resistance of glioblastoma stem cells. Cell Death Differ 2006;13: 1238-1241.
4. Liu G, Yuan X, Zeng Z, et al. Analysis of gene expression and chemoresistance of CD133+ cancer stem cells in glioblastoma. Mol Cancer 2006;5:67.
5. De Vleeschouwer S, Van Calenbergh F, Demaerel P, et al. Transient local response and persistent tumor control of recurrent malignant glioma treated with combination therapy including dendritic cell therapy. J Neurosurg (Pediatr) 2004;100:492-497.
6. De Vleeschouwer S, Van Gool SW, Van Calenbergh F. Immunotherapy for malignant gliomas: Emphasis on strategies of active specific immunotherapy using autologous dendritic cells. Childs Nerv Syst 2005;21:7-18.
7. De Vleeschouwer S, Arredouani M, Ade M, et al. Uptake and presentation of malignant glioma tumor cell lysates by monocyte-derived dendritic cells. Cancer Immunol Immunother 2005;54: 372-382.
8. De Vleeschouwer S, Rapp M, Sorg RV, et al. Dendritic cell vaccination in patients with malignant gliomas: Current status and future directions. Neurosurgery 2006;59:988-999.
9. De Vleeschouwer S, Fieuws S, Rutkowski S, et al. Postoperative adjuvant dendritic cell-based immunotherapy in patients with relapsed glioblastoma multiforme. Clin Cancer Res 2008;14: 3098-3104.
10. Massimino M, Gandola L, Luksch R, et al. Sequential chemotherapy, high-dose thiotepa, circulating progenitor cell rescue, and radiotherapy for childhood high-grade glioma. Neuro Oncol 2005; 7:41-48.
11. Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 1976;72:248-254.
12. Rutkowski S, De Vleeschouwer S, Kaempgen E, et al. Surgery and adjuvant dendritic cell-based tumour vaccination for patients with relapsed malignant glioma, a feasibility study. Br J Cancer 2004; 91:1656-1662.
13. Macdonald DR, Cascino TL, Schold SC, Jr., et al. Response criteria for phase II studies of supratentorial malignant glioma. J Clin Oncol 1990;8:1277-1280.
14. Wolff JE, Daumling E, Dirksen A, et al. Munster Heidelberg Abilities Scale - A measuring instrument for global comparison of illness sequelae. Klin Padiatr 1996;208:294-298.
15. Yoshida S, Morii K, Watanabe M, et al. The generation of antitumoral cells using dendritic cells from the peripheral blood of patients with malignant brain tumors. Cancer Immunol Immunother 2001;50:321-327.
16. Okada H, Tahara H, Shurin MR, et al. Bone marrow-derived dendritic cells pulsed with a tumor-specific peptide elicit effective anti-tumor immunity against intracranial neoplasms. Int J Cancer 1998;78:196-201.
17. Siesjo P, Visse E, Sjogren HO. Cure of established, intracerebral rat gliomas induced by therapeutic immunizations with tumor cells and purified APC or adjuvant IFN-gamma treatment. J Immunother Emphasis Tumor Immunol 1996;19:334-345.
18. Kikuchi T, Akasaki Y, Irie M, et al. Results of a phase I clinical trial of vaccination of glioma patients with fusions of dendritic and glioma cells. Cancer Immunol Immunother 2001;50:337-344.
19. Kikuchi T, Akasaki Y, Abe T, et al. Vaccination of glioma patients with fusions of dendritic and glioma cells and recombinant human interleukin 12. J Immunother 2004;27:452-459.
20. Liau LM, Black KL, Martin NA, et al. Treatment of a Glioblastoma patient by vaccination with autologous dendritic cells pulsed with allogeneic major histocompatibility complex class I-matched tumor peptides: Case report. Neurosurg Focus 2000;9:e8.Available at: http://www.medscape.com/viewarticle/ 405669.
21. Liau LM, Prins RM, Kiertscher SM, et al. Dendritic cell vaccination in glioblastoma patients induces systemic and intracranial T-cell responses modulated by the local central nervous system tumor microenvironment. Clin Cancer Res 2005;11:5515-5525.
22. Wheeler CJ, Black KL, Liu G, et al. Thymic CD8(+) T cell production strongly influences tumor antigen recognition and age-dependent glioma mortality. J Immunol 2003;171:4927-4933.
23. Yamanaka R, Abe T, Yajima N, et al. Vaccination of recurrent glioma patients with tumour lysate-pulsed dendritic cells elicits immune responses: Results of a clinical phase I/II trial. Br J Cancer 2003;89:1172-1179.
24. Yamanaka R, Homma J, Yajima N, et al. Clinical evaluation of dendritic cell vaccination for patients with recurrent glioma: Results of a clinical phase I/II trial. Clin Cancer Res 2005;11: 4160-4167.
25. Yu JS, Wheeler CJ, Zeltzer PM, et al. Vaccination of malignant glioma patients with peptide-pulsed dendritic cells elicits systemic cytotoxicity and intracranial T-cell infiltration. Cancer Res 2001; 61:842-847.
26. Yu JS, Liu G, Ying H, et al. Vaccination with tumor lysate-pulsed dendritic cells elicits antigen-specific, cytotoxic T-cells in patients with malignant glioma. Cancer Res 2004;64:4973-4979.
27. Korones DN, Smith A, Foreman N, et al. Temozolomide and oral VP-16 for children and young adults with recurrent or treatment-induced malignant gliomas. Pediatr Blood Cancer 2006;47:37-41.
28. Finlay JL, Goldman S, Wong MC, et al. Pilot study of high-dose thiotepa and etoposide with autologous bone marrow rescue in children and young adults with recurrent CNS tumors. The Children's Cancer Group. J Clin Oncol 1996;14:2495-2503.
29. Chamberlain MC. Recurrent supratentorial malignant gliomas in children. Long-term salvage therapy with oral etoposide. Arch Neurol 1997;54:554-558.
30. Lashford LS, Thiesse P, Jouvet A, et al. Temozolomide in malignant gliomas of childhood: A United Kingdom Children's Cancer Study Group and French Society for Pediatric Oncology Intergroup Study. J Clin Oncol 2002;20:4684-4691.
31. Needle MN, Molloy PT, Geyer JR, et al. Phase II study of daily oral etoposide in children with recurrent brain tumors and other solid tumors. Med Pediatr Oncol 1997;29:28-32.
32. Verschuur AC, Grill J, Lelouch-Tubiana A, et al. Temozolomide in paediatric high-grade glioma: A key for combination therapy? Br J Cancer 2004;91:425-429.
33. Wheeler CJ, Das A, Liu G, et al. Clinical responsiveness of glioblastoma multiforme to chemotherapy after vaccination. Clin Cancer Res 2004;10:5316-5326.
34. Muller AJ, Prendergast GC. Marrying immunotherapy with chemotherapy: Why say IDO? Cancer Res 2005;65:8065-8068.
35. Nowak AK, Robinson BW, Lake RA. Synergy between chemotherapy and immunotherapy in the treatment of established murine solid tumors. Cancer Res 2003;63:4490-4496.
36. Masucci GV, Mansson-Brahme E, Ragnarsson-Olding B, et al. Alternating chemo-immunotherapy with temozolomide and low-dose interleukin-2 in patients with metastatic melanoma. Melanoma Res 2006;16:357-363.
37. Liu G, Akasaki Y, Khong HT, et al. Cytotoxic T cell targeting of TRP-2 sensitizes human malignant glioma to chemotherapy. Oncogene 2005;24:5226-5234.
38. Burger PC, Yu IT, Tihan T, et al. Atypical teratoid/rhabdoid tumor of the central nervous system: Ahighly malignant tumor of infancy and childhood frequently mistaken for medulloblastoma: A Pediatric Oncology Group study. Am J Surg Pathol 1998;22: 1083-1092.
39. Packer RJ, Biegel JA, Blaney S, et al. Atypical teratoid/rhabdoid tumor of the central nervous system: Report on workshop. J Pediatr Hematol Oncol 2002;24:337-342.
40. Rorke LB, Packer RJ, Biegel JA. Central nervous system atypical teratoid/rhabdoid tumors of infancy and childhood: Definition of an entity. J Neurosurg 1996;85:56-65.
41. Jacobs JF, Hoogerbrugge PM, de Rakt MW, et al. Phenotypic and functional characterization of mature dendritic cells from pediatric cancer patients. Pediatr Blood Cancer 2007;49:924-927.